Benefits Of Omega 3s Still Unclear For Bipolar Disorder
Despite intriguing findings that omega 3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega 3s are useful treatments for people with bipolar disorder, according to a review of recent studies.
Perceptual Switch Rates With Ambiguous Structure-from-motion Figures In Bipolar Disorder
Most people believe that the way we see things is affected by how we feel emotionally. Does our mood really change what we see or do individuals with certain genetic traits always tend to see things differently, regardless of their mood? Earlier research suggested that people with bipolar mood disorder might alternate their perception more slowly when looking at ambiguous figures.
Report Confirms Increased Risk Of Smoking, Substance Abuse In Bipolar Adolescents
A study from the Massachusetts General Hospital (MGH) supports previous reports that adolescents with bipolar disorder are at increased risk for smoking and substance abuse. The article appearing in the June Drug and Alcohol Dependence - describing the largest such investigation to date and the first to include a control group - also indicates that bipolar-associated risk is independent of the risk conferred by other disorders affecting study participants.
Repligen Announces Plans To Initiate A Phase 2b Trial For RG2417 In Bipolar Disorder
Repligen Corporation (Nasdaq: RGEN) announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar disorder later this year.
Antidepressants Alone: Not For Bipolar Depression
Psychiatrists have cautioned against the use of antidepressants alone in people with bipolar disorders, saying they could worsen a patient's condition by causing a destabilisation in mood.
Alcohol Dependence May Respond To Aripiprazole, Treatment For Bipolar Disorder And Schizophrenia.
* Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. * A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol.
Overview Of Asenapine Data From Olympia Trial Program Presented At American Psychiatric Association Annual Meeting
Schering-Plough Corporation (NYSE: SGP) announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washington, D.C., May 3-8. Data from the studies, involving patients with bipolar I disorder and schizophrenia, were presented in two oral presentations (Abstracts # 44 and # 80).
Study Suggests Risperidone Long Acting Injection Combined With Standard Treatment Helped Delay Time To Relapse In Patients With Bipolar Disorder
Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.
Scientists Discover Chemical Signature Of Manic Depression
People with manic depression have a distinct chemical signature in their brains, according to a new study. The research, published in the journal Molecular Psychiatry, may also indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to cause.
ACADIA Announces Presentation Of Data On Pimavanserin Co-Therapy At The 14th Biennial Winter Workshop On On Schizophrenia And Bipolar Disorders
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Murray Rosenthal, D.